PDF(Pubmed)
Abstract：
UNASSIGNED: Roxadustat, the first-in-class drug for the treatment of renal anemia, has demonstrated efficacy in renal anemia with microinflammation. Additional data are needed regarding the efficacy of roxadustat on renal anemia with systemic macroinflammation.
UNASSIGNED: Three cohorts of renal anemia based on the basic level of high-sensitivity CRP were included. Patients with hsCRP ≤2 mg/L were selected as non-inflammation (NI) group; 2< hsCRP ≤10 mg/L as microinflammation (MI) group; hsCRP≥10 mg/L as macroinflammation (MA) group. Patients received oral roxadustat three times per week for 52 weeks. The primary end point was the hemoglobin level over weeks 12-52. The second end point was the cumulative proportion of patients achieving hemoglobin response by the end of week 12.
UNASSIGNED: A total of 107 patients with chronic kidney diseases (CKDs) were enrolled. Overall, the baseline hemoglobin level of patients was 79.99 ± 11.20 g/L. Roxadustat could significantly increase the hemoglobin level in all of the three groups and did not show any significant difference (p > 0.05, respectively). Meanwhile, compared with that of the NI group, there was no significant difference in hemoglobin response rate in the MA group both at week 12 (p = 0.06; 95% confidence interval [CI], 0.9531-13.75) and week 52 (p = 0.37; 95% CI, 0.5080-7.937). Moreover, the hemoglobin response was independent of baseline hsCRP level (p = 0.72, 95% CI, -0.1139 to 0.0794). More importantly, roxadustat significantly reduced ferritin and serum iron levels and increased total iron-binding capacity in the three groups, which showed no significant differences among the three groups (p > 0.05, respectively).
UNASSIGNED: Roxadustat significantly improves anemia in CKD patients with systemic macroinflammation.
UNASSIGNED: Three cohorts of renal anemia based on the basic level of high-sensitivity CRP were included. Patients with hsCRP ≤2 mg/L were selected as non-inflammation (NI) group; 2< hsCRP ≤10 mg/L as microinflammation (MI) group; hsCRP≥10 mg/L as macroinflammation (MA) group. Patients received oral roxadustat three times per week for 52 weeks. The primary end point was the hemoglobin level over weeks 12-52. The second end point was the cumulative proportion of patients achieving hemoglobin response by the end of week 12.
UNASSIGNED: A total of 107 patients with chronic kidney diseases (CKDs) were enrolled. Overall, the baseline hemoglobin level of patients was 79.99 ± 11.20 g/L. Roxadustat could significantly increase the hemoglobin level in all of the three groups and did not show any significant difference (p > 0.05, respectively). Meanwhile, compared with that of the NI group, there was no significant difference in hemoglobin response rate in the MA group both at week 12 (p = 0.06; 95% confidence interval [CI], 0.9531-13.75) and week 52 (p = 0.37; 95% CI, 0.5080-7.937). Moreover, the hemoglobin response was independent of baseline hsCRP level (p = 0.72, 95% CI, -0.1139 to 0.0794). More importantly, roxadustat significantly reduced ferritin and serum iron levels and increased total iron-binding capacity in the three groups, which showed no significant differences among the three groups (p > 0.05, respectively).
UNASSIGNED: Roxadustat significantly improves anemia in CKD patients with systemic macroinflammation.
摘要：
■Roxadustat,治疗肾性贫血的一流药物，已证明对微炎症的肾性贫血有效。关于罗沙司他对系统性宏观炎症的肾性贫血的疗效，还需要其他数据。
■纳入三个基于高敏CRP基本水平的肾性贫血队列。选择hsCRP≤2mg/L的患者作为非炎症（NI）组；2■共纳入107例慢性肾脏病(CKDs)患者。总的来说,患者的基线血红蛋白水平为79.99±11.20g/L。Roxadustat可以显着提高三组的血红蛋白水平，并且没有显着差异（分别为p>0.05）。同时,与NI组相比，在第12周时，MA组的血红蛋白反应率没有显着差异（p=0.06;95％置信区间[CI]，0.9531-13.75）和第52周（p=0.37；95%CI，0.5080-7.937）。此外，血红蛋白反应独立于基线hsCRP水平(p=0.72,95%CI,-0.1139~0.0794).更重要的是,在三组中，罗沙他显着降低了铁蛋白和血清铁水平，并增加了总铁结合能力，三组间差异无统计学意义(p>0.05)。
■Roxadustat可显著改善CKD伴全身性宏观炎症患者的贫血。
■纳入三个基于高敏CRP基本水平的肾性贫血队列。选择hsCRP≤2mg/L的患者作为非炎症（NI）组；2
■Roxadustat可显著改善CKD伴全身性宏观炎症患者的贫血。
